Unique ID issued by UMIN | UMIN000036835 |
---|---|
Receipt number | R000041964 |
Scientific Title | DAA therapy and ADAMTS13/VWF for HCV |
Date of disclosure of the study information | 2020/01/01 |
Last modified on | 2019/05/23 20:25:56 |
DAA therapy and ADAMTS13/VWF for HCV
DAA therapy and ADAMTS13/VWF for HCV
DAA therapy and ADAMTS13/VWF for HCV
DAA therapy and ADAMTS13/VWF for HCV
Japan |
hepatitis type C
Hepato-biliary-pancreatic medicine |
Others
NO
To investigate whether ADAMTS13/VWF is associated with functional liver capacity for hepatitis C patients receiving DAA therapy
Efficacy
Portal hypertension
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1)> 20 years old
2)The patients obtained the consent
1)The impossible of oral intake
2)The pharmacokinetics is changed for patient's condition
3)The necessary medicine change the pharmacokinetics of rifaximin
4)The pregnancy and lactating
5)The allergy of rifaximin
6)The outcome evaluation is difficult for patient's condition
7)The execution plan of achievement is difficult
50
1st name | Hiroaki |
Middle name | |
Last name | Takaya |
Nara medical unversity
3rd departemnt of interanal medicine
6348521
840, Shijo-cho, Kashihara, Nara
0744223051
htky@naramed-u.ac.jp
1st name | Hiroaki |
Middle name | |
Last name | Hiroaki |
Nara medical unversity
3rd departemnt of interanal medicine
6348521
840, Shijo-cho, Kashihara, Nara
0744223051
htky@naramed-u.ac.jp
Nara Medical University
Japan Agency for Medical Research and Developmen
Japanese Governmental office
Nara medical unversity
840, Shijo-cho, Kashihara, Nara
0744223051
htky@naramed-u.ac.jp
NO
2020 | Year | 01 | Month | 01 | Day |
Unpublished
Preinitiation
2019 | Year | 12 | Month | 31 | Day |
2020 | Year | 01 | Month | 01 | Day |
2024 | Year | 03 | Month | 31 | Day |
nothing
2019 | Year | 05 | Month | 23 | Day |
2019 | Year | 05 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041964